AI Tools for Radiologists, Pathologists & Medical Imaging Specialists 2026 — Top 23 Picks for 2026

The 2026 AI toolkit for radiologists, pathologists, ER physicians, cardiologists, oncologists, primary-care doctors, PACS administrators, and medical AI vendor adoption leads. Aidoc (Israel $240M, CT stroke/PE/cervical fracture/brain hemorrhage AI standard, 1,500 US hospitals / Europe / Israel / Japan, 12 FDA clearances, Nvidia / General Catalyst backed, 20M cases, -50% diagnosis time), Viz.ai (US $252M, #1 FDA-cleared stroke LVO (large vessel occlusion) detection, Mount Sinai / Mayo Clinic, -39 min Door-to-Needle Time, 5M scans, Insight Partners / Greenoaks backed), PathAI (US $255M, pathology AI standard, Roche / BMS / Bayer drug-discovery partnerships, Harvard Medical School origin, 5,000 US pathologists, AI diagnosis + human review, Series C unicorn $1B+), Tempus AI (US NASDAQ:TEM $10B mkt cap, cancer genomics + imaging + EHR, AI Precision Oncology, Eric Lefkofsky (Groupon) founded, 3,000 US hospitals, AI drug discovery, 2024 IPO), Annalise.ai (Australia $70M, chest X-ray AI detecting 124 findings (industry max), US FDA clearance, Harrison.ai sister company, Royal Australian / UK NHS, -40% missed diagnoses), Cleerly (US $381M, coronary CT-Angio AI, heart-attack prevention, Mayo / Cleveland Clinic, Insight Partners backed, cardiology AI unicorn), RapidAI (US $75M, stroke Penumbra/CTA/Perfusion AI, Stanford origin, 2,000 US hospitals, Viz.ai competitor), Paige.AI (US $220M, #1 FDA-cleared pathology AI for prostate cancer, Memorial Sloan Kettering origin, Goldman Sachs backed), Lunit (Korea KOSDAQ:328130 $4B mkt cap, chest X-ray / mammography AI, Korea / Europe / GE HealthCare partnership, KOSDAQ-listed, 10K hospitals), Qure.ai / Butterfly Network / iCAD (Qure.ai India chest X-ray AI WHO adoption, Butterfly Network NYSE:BFLY portable ultrasound AI J&J acquisition, iCAD ProFound AI mammography 3,000 US sites), HeartFlow (coronary plaque AI), Hologic Genius AI / Volpara Health (mammography), BoneXpert / Gleamer BoneView (bone age / fracture), IDx-DR (FDA's first AI clearance 2018, diabetic retinopathy, Walmart / CVS), SkinVision / Skinive / DermAssist (skin AI, 2M downloads, EU/Oceania medical-device clearance), GE HealthCare Edison / Siemens Healthineers AI-Rad Companion / Philips IntelliSpace AI / Bayer Calantic / Nuance PowerScribe One (PACS integration), Microsoft Rad-DINO / Google Med-PaLM 2 / Meta DINOv2-Medical (Foundation Models), and ELPIXEL EIRL / AI Medical Service (Japan domestic) power stroke emergency diagnosis, pulmonary embolism CT, chest X-ray AI 124 findings, mammography AI for breast cancer, pathology AI, coronary CT AI, fundus AI for diabetic retinopathy, skin AI for skin cancer, portable ultrasound AI, and cancer genomics + imaging precision oncology — delivering -50% diagnosis time, -40% misses, -39 min stroke Door-to-Needle, +30% stroke survival, +30% radiologist productivity, -50% drug-development time, specialist-shortage relief, 700+ US FDA clearances, $50B market by 2030, reimbursement bonus for AI imaging, and 5-50x ROI. Optimal 2026 stacks by specialty: (A) radiology CT/MRI ($50K-200K/yr) - Aidoc Suite $100K/yr + Viz.ai + RapidAI = $200K/yr, -50% emergency diagnosis, -40% misses, -30% radiologist overtime, 5-15x ROI; (B) pathology AI ($100K-500K/yr) - PathAI Enterprise + Paige.AI = $300K/yr, +15% diagnostic agreement, pathologist-shortage relief, +$10-100M Roche drug revenue, 50-300x ROI; (C) mammography sites ($30K-100K/yr) - Lunit INSIGHT MMG + iCAD = $50K/yr, -30% misses, -40% radiologist workload, CMS reimbursement, 5-10x ROI; (D) emergency departments ($100K-300K/yr) - Aidoc CT + Viz.ai LVO + RapidAI Stroke = $200K/yr, -39 min Door-to-Needle, +30% survival, -50% litigation, 10-20x ROI; (E) primary care / clinics ($10K-50K/yr) - IDx-DR fundus + Butterfly ultrasound + DermAssist skin = $30K/yr, early diabetes / skin cancer detection, CMS reimbursement, +50% referrals, 3-10x ROI; (F) cancer genomics + imaging precision oncology - Tempus AI + PathAI, 3,000 US hospitals, AI drug discovery; (G) PACS integration workflow - GE Edison + Siemens AI-Rad + Philips IntelliSpace + Bayer Calantic, multi-AI marketplace; (H) Japan market PMDA AI clearance - ELPIXEL EIRL + AI Medical Service + Aidoc Japan + Lunit Japan, 2024 reimbursement bonus for AI imaging. Global Medical AI is $15B in 2024 - $50B by 2030 (35% CAGR); Radiology AI $10B in 2024 - $30B by 2030; 700+ FDA AI/ML clearances (420 radiology / 60%, 15% cardiovascular); Aidoc 1,500 US hospitals / 20M cases; Viz.ai 5M scans / -39 min Door-to-Needle; PathAI 5,000 US pathologists / Roche partnership; Tempus AI NASDAQ-listed $10B mkt cap; Lunit KOSDAQ $4B; ACR / ESR / RSNA AI Bias warnings and guidelines; US CMS 2024 new AI reimbursement codes; Japan PMDA 50+ AI medical-device clearances; 2024 reimbursement bonus for AI imaging diagnostics; ELPIXEL EIRL domestic chest X-ray; ¥300B market by 2030. Five risk-mitigations: FDA clearance / regulatory risk (Class II/III required, uncleared = malpractice / litigation / no reimbursement; verify FDA 510(k) clearance, CE Mark Europe, PMDA Japan; favor 700+ FDA-cleared AIs (Aidoc / Viz.ai / PathAI); uncleared AI is research only); false positives / negatives (Lunit false-negative breast-cancer lawsuits, Aidoc false positives, ACR / RSNA AI Bias warnings; AI as 2nd reader with radiologist final call, verify published sensitivity/specificity, multi-AI comparison Aidoc+Lunit, re-evaluate every 3 months); HIPAA / GDPR patient data leakage ($1M HIPAA fines, Viz.ai 2024 breach allegations, EU AI Act 2026 medical AI high-risk; HIPAA BAA contract, SOC2 Type II / ISO 27001, local processing - GE Healthcare Edison On-Premise, opt-in patient consent); radiologist pushback / job fears (Hinton 2016 'radiologists obsolete' remark, ACR / RSNA pushback, AI as supportive not replacement, salary concerns; AI as co-pilot with +30% productivity, specialist-shortage relief, ACR Acceptable Use Policy, ESR European guidelines); reimbursement / monetization difficulty (no US CMS code initially, Aidoc / Viz.ai out-of-pocket for hospitals, immature European reimbursement; track US CMS 2024 new AI reimbursement codes, Aidoc Value-Based Care, hospital ROI from reduced litigation, stroke-survival improvement drives reimbursement). Seven 2026 trends: FDA AI/ML clearances cross 700 (2024, 60% radiology / 15% cardiovascular, accelerating pace, industry standardization); Foundation Models for healthcare (Google Med-PaLM 2 / Microsoft RAD-DINO / Meta DINOv2-Medical, generalist medical AI, multi-organ / multi-modality, +20% diagnostic accuracy); multimodal integration (imaging + genomics + EHR, Tempus AI pioneer, imaging + RNA-Seq + EHR, precision oncology, BMS / Roche new drugs); AI drug discovery (PathAI / Tempus / Recursion, Roche / BMS / Bayer partnerships, AlphaFold linkage, -50% drug-development time); EU AI Act 2026 enforcement (medical AI high-risk, GDPR Art 22, CE Mark MDR strengthening, $30M fines); Japan market (PMDA 50+ AI medical-device clearances, 2024 reimbursement bonus for AI imaging diagnostics, ELPIXEL EIRL / AI Medical Service domestic, ¥300B by 2030); generative AI radiology reports (Microsoft Rad-DINO / Google Med-PaLM 2 - CT/MRI image - automated AI report - Microsoft Nuance Dragon Ambient eXperience (DAX), -50% radiologist time). Roadmap: Week 1 - assess FDA-cleared AIs + vendor demos; Month 1 - pilot Aidoc / Viz.ai; Months 2-3 - expand to other modalities (mammography / pathology / fundus); Year 1 - -50% diagnosis time + +30% survival; Year 2 - Foundation Models (Med-PaLM 2 / Rad-DINO) integration; Year 3 - PMDA approval + reimbursement bonus + EU AI Act compliance fully deployed.